Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy

Pancreatic cancer is the most common lethal tumor in America. This lethality is related to limited treatment options. Conventional treatments involve the non-specific use of chemotherapeutical agents such as 5-FU, capecitabine, gemcitabine, paclitaxel, cisplatin, oxaliplatin, or irinotecan, which pr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jorge A. Roacho-Pérez, Elsa N. Garza-Treviño, Paulina Delgado-Gonzalez, Zuca G-Buentello, Juan Luis Delgado-Gallegos, Christian Chapa-Gonzalez, Margarita Sánchez-Domínguez, Celia N. Sánchez-Domínguez, Jose Francisco Islas
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	pancreatic cancer molecular markers target therapy nanomedicine Science Q
Acceso en línea:	https://doaj.org/article/205d352e61ba491d8955bb9be25ba703
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:205d352e61ba491d8955bb9be25ba703
record_format	dspace
spelling	oai:doaj.org-article:205d352e61ba491d8955bb9be25ba7032021-11-25T18:11:00ZTarget Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy10.3390/life111111872075-1729https://doaj.org/article/205d352e61ba491d8955bb9be25ba7032021-11-01T00:00:00Zhttps://www.mdpi.com/2075-1729/11/11/1187https://doaj.org/toc/2075-1729Pancreatic cancer is the most common lethal tumor in America. This lethality is related to limited treatment options. Conventional treatments involve the non-specific use of chemotherapeutical agents such as 5-FU, capecitabine, gemcitabine, paclitaxel, cisplatin, oxaliplatin, or irinotecan, which produce several side effects. This review focuses on the use of targeted nanoparticles, such as metallic nanoparticles, polymeric nanoparticles, liposomes, micelles, and carbon nanotubes as an alternative to standard treatment for pancreatic cancer. The principal objective of nanoparticles is reduction of the side effects that conventional treatments produce, mostly because of their non-specificity. Several molecular markers of pancreatic cancer cells have been studied to target nanoparticles and improve current treatment. Therefore, properly functionalized nanoparticles with specific aptamers or antibodies can be used to recognize pancreatic cancer cells. Once cancer is recognized, these nanoparticles can attack the tumor by drug delivery, gene therapy, or hyperthermia.Jorge A. Roacho-PérezElsa N. Garza-TreviñoPaulina Delgado-GonzalezZuca G-BuentelloJuan Luis Delgado-GallegosChristian Chapa-GonzalezMargarita Sánchez-DomínguezCelia N. Sánchez-DomínguezJose Francisco IslasMDPI AGarticlepancreatic cancermolecular markerstarget therapynanomedicineScienceQENLife, Vol 11, Iss 1187, p 1187 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pancreatic cancer molecular markers target therapy nanomedicine Science Q
spellingShingle	pancreatic cancer molecular markers target therapy nanomedicine Science Q Jorge A. Roacho-Pérez Elsa N. Garza-Treviño Paulina Delgado-Gonzalez Zuca G-Buentello Juan Luis Delgado-Gallegos Christian Chapa-Gonzalez Margarita Sánchez-Domínguez Celia N. Sánchez-Domínguez Jose Francisco Islas Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy
description	Pancreatic cancer is the most common lethal tumor in America. This lethality is related to limited treatment options. Conventional treatments involve the non-specific use of chemotherapeutical agents such as 5-FU, capecitabine, gemcitabine, paclitaxel, cisplatin, oxaliplatin, or irinotecan, which produce several side effects. This review focuses on the use of targeted nanoparticles, such as metallic nanoparticles, polymeric nanoparticles, liposomes, micelles, and carbon nanotubes as an alternative to standard treatment for pancreatic cancer. The principal objective of nanoparticles is reduction of the side effects that conventional treatments produce, mostly because of their non-specificity. Several molecular markers of pancreatic cancer cells have been studied to target nanoparticles and improve current treatment. Therefore, properly functionalized nanoparticles with specific aptamers or antibodies can be used to recognize pancreatic cancer cells. Once cancer is recognized, these nanoparticles can attack the tumor by drug delivery, gene therapy, or hyperthermia.
format	article
author	Jorge A. Roacho-Pérez Elsa N. Garza-Treviño Paulina Delgado-Gonzalez Zuca G-Buentello Juan Luis Delgado-Gallegos Christian Chapa-Gonzalez Margarita Sánchez-Domínguez Celia N. Sánchez-Domínguez Jose Francisco Islas
author_facet	Jorge A. Roacho-Pérez Elsa N. Garza-Treviño Paulina Delgado-Gonzalez Zuca G-Buentello Juan Luis Delgado-Gallegos Christian Chapa-Gonzalez Margarita Sánchez-Domínguez Celia N. Sánchez-Domínguez Jose Francisco Islas
author_sort	Jorge A. Roacho-Pérez
title	Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy
title_short	Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy
title_full	Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy
title_fullStr	Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy
title_full_unstemmed	Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy
title_sort	target nanoparticles against pancreatic cancer: fewer side effects in therapy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/205d352e61ba491d8955bb9be25ba703
work_keys_str_mv	AT jorgearoachoperez targetnanoparticlesagainstpancreaticcancerfewersideeffectsintherapy AT elsangarzatrevino targetnanoparticlesagainstpancreaticcancerfewersideeffectsintherapy AT paulinadelgadogonzalez targetnanoparticlesagainstpancreaticcancerfewersideeffectsintherapy AT zucagbuentello targetnanoparticlesagainstpancreaticcancerfewersideeffectsintherapy AT juanluisdelgadogallegos targetnanoparticlesagainstpancreaticcancerfewersideeffectsintherapy AT christianchapagonzalez targetnanoparticlesagainstpancreaticcancerfewersideeffectsintherapy AT margaritasanchezdominguez targetnanoparticlesagainstpancreaticcancerfewersideeffectsintherapy AT celiansanchezdominguez targetnanoparticlesagainstpancreaticcancerfewersideeffectsintherapy AT josefranciscoislas targetnanoparticlesagainstpancreaticcancerfewersideeffectsintherapy
_version_	1718411485211787264

Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy

Ejemplares similares